6Zhou HM,Nichols A,Meda P,et al.Urokinase-type plasminogen activator and its receptor to synergize to promote pathogenic proteolysis.EMBO J ,2000,19(17),4817.
2Muller GA,Zeisberg M,Strutz F.The importance of tubulointerstitial damage in progressive renal disease.Nephrol Dial Transplant,2000,15(Suppl 6):76-77.
3Nangaku M.Mechanisms of tubulointerstitial injury in the kidney:final common pathways to end-stage renal failure.Intern Med,2004,43(1):9-17.
4Manotham K,Tanaka T,Matsumoto M,et al.Transdifferentiation of cultured tubular cells induced by hypoxia.Kidney Int,2004,65(3):871-880.
5Lama G,Ferraraccio F,Iaccarino F,et al.Pelviureteral junction obstruction:correlation of renal cell apoptosis and differential renal function.J Urol,2003,169(6):2335-2238.
6Jinde K,Nikolic-Paterson DJ,Huang XR,et al.Tubular phemtypic change in progressive tubulointerstitial fibrosis in human glomerulonephritis.Am J Kidney Dis,2001,38(4):761-763.
7Nicholas SB.Advances in pathogenetic mechanisms of diabetic nephropathy.Cell Mol Biol (Noisy-le-grand),2003,49(8):1319-1325.
8David PB.The transforming growth factor beta system in kidney disease and repir recent progress and future directions.Curr Orin Nephrol Hypertens,1999,(8):21-30.
9Tsuyoshi O, Michael F, Wilbur L, et al. Modulation od plasmanogen activator inhibitor-1 in vivo:A new mechanism for the anti-fibrotic effect of rennin-agiotensin inhibitor.Kidney Int, 1997,51:164-172.
10Yoshida Y, Shiiki H, Iwano M, et al. Enhanced expression of plasminogen activator inhibitor 1 in patients with nephrotic syndrome. Nephron,2001,88(1):24-29.
5Merkle M, Ribeiro A, Koppel S, et al. TNF-(~ en- hances TLR3-dependent effects on MMP-9 ex- pression in human mesangial cells [J]. Cell Biol Int, 2012, 36(12) : 1155 -1160.
6Hoashi T, Kadono T, Kikuchi K, et al. Differentia] growth regulation in human melanoma cell lines by TIMP-1 and TIMP-2[J].Biochem Biophs Res Commun, 2001,288(2) : 371.
